Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Large joint inflammatory arthritis induced by pembrolizumab in metastatic melanoma (#234)

Vanessa Wong 1 , Stephen Brown 1 , Bhaumik Shah 1
  1. Oncology, Ballarat Health Services, Ballarat, Victoria, Australia

Despite the growing indications of immune checkpoint inhibitors to treat advanced stage cancers, true inflammatory arthritis is an infrequently reported immune-related adverse event. Arthralgia is commonly reported in clinical trials with prevalence ranging from 1-43%1, with no clear breakdown of grade or management paradigm.

Case report:
We report a case of evolving large joint polyarticular inflammatory arthritis, limiting mobility, in a 55 year old male patient receiving pembrolizumab for metastatic melanoma after 10 months on therapy. At the onset of arthritis, PET/CT demonstrated complete tumour response and is durable 8 months later. This patient obtained good symptomatic control with cessation of pembrolizumab, three months of weaning prednisolone and opioid analgesia. Inflammatory arthritis was demonstrated by imaging, synovial fluid aspirate and synovial biopsy.

A review of the limited number of case reports, most with combination anti-PD1 and anti CTLA-4 agents, have management that vary from intra-articular glucocorticoids to systemic glucocorticoids, escalating to steroid sparing agents and anti-tumour necrosis factor medications. There appears to be a dichotomy between treating teams who administered glucocorticoid therapy and those who avoided use. Additionally, the majority of patients who developed inflammatory arthritis had either partial or complete tumour response, with unclear prognostic significance2-6. Future research is required to formulate a validated treatment algorithm to aid oncologists in management of this often disabling rheumatological adverse event.

  1. Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken). 2016.
  2. Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412
  3. Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43-50
  4. Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38(1):37-9
  5. Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J. Could knee inflammatory synovitis be induced by pembrolizumab? J Oncol Pharm Pract.
  6. Salmon JH, Lambrecht I, Brochot P, Grange F. A case of arthritis under pembrolizumab. Joint Bone Spine. 2017;84(2):243-4